Peanut oral immunotherapy in a capsule is moving closer to regulatory approval in the United States. The therapy brings hope – not for a cure – but of lives made less vulnerable.
The U.S. Department of Justice has found that a theater company violated a food-allergic boy’s rights.
Allergic Living speaks to U.K. detective and prosecutor on allergy manslaughter case.
Mother warns of precautions and communication needed to prevent tragedies like her daughter’s.
Flour supplier sees link to cross-contact with peanut dust in field or in handling.
Why FARE (Food Allergy Research & Education) thinks desensitization is a vital food allergy therapy on the path toward finding tolerance.
The new guidelines for the introduction of peanut in both the healthy infants and those at high risk for allergy will become an addendum to NIAID’s 2010 Guidelines for the Diagnosis and Management of Food Allergies. Following is a summary of the draft guidance for high-risk children: ‘High risk’ is defined as a baby who… Read more »
If you felt a sense of trepidation after reading the results of the new LEAP-On follow-up study, you’re not alone – many people in the food allergy community are going through a bout of culture shock. There’s no denying that the results of 2015’s LEAP and this month’s LEAP-On are quite phenomenal – a 74… Read more »
A pharmaceutical approach to oral immunotherapy is a step closer to approval by the Food and Drug Administration. The treatment, called AR101, is being developed by a company called Aimmune Therapeutics. The company’s aim is to make people less allergic to peanuts by having them take a specially formulated peanut powder in increasing doses over… Read more »